Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 08:20 save search
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
Published: 2023-07-16 (Crawled : 08:20) - globenewswire.com
ABOS | $3.18 0.63% 0.32% 150K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
acu193 conference disease association alzheimer’s positive international pharmaceuticals topline results study
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-01-07 (Crawled : 08:20) - prnewswire.com
BIIB | $201.99 4.56% 4.32% 420
|
Health Technology
| Email alert
Add to watchlist
treatment fda disease alzheimer's application license approval
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
Published: 2022-06-18 (Crawled : 08:20) - biospace.com/
ACAD | News | $16.59 -0.9% -1.03% 1.3M
|
Health Technology
| Email alert
Add to watchlist
nuplazid treatment fda disease alzheimer’s alzheimer's
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.